MASHINIi

EDAP TMS S.A..

EDAP.US | Manufacture of medical and dental instruments and supplies

EDAP TMS S.A. is a global medical technology company focused on urology. The company develops, manufactures, and markets minimally invasive medical devices for the treatment of urological diseases, primarily focused on high-intensity focused ultrasound (HIFU) for prostate cancer and kidney stone tre...Show More

Ethical Profile

Mixed.

EDAP TMS S.A. shows a strong commitment to patient health through its minimally invasive urology devices. The HIFI study, involving 3,328 patients, found Focal One robotic HIFU for prostate cancer to be non-inferior to radical prostatectomy, with better urinary continence and erectile function outcomes. US Medicare reimbursement for Focal One HIFU increased significantly from $4,506 to $8,558 per procedure, potentially enhancing patient access, complemented by positive reimbursement opinions in France. However, specific data on price accessibility for vulnerable populations, fair labor practices, ethical sourcing, environmental impact, or broader business ethics is largely unavailable, leading to a mixed ethical profile.

Value Scores

Better Health for All10
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons-50
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

10

EDAP's core product, Focal One HIFU for prostate cancer, demonstrates substantial health benefits. The HIFI study, a large prospective, multi-center clinical trial with 3,328 patients, showed non-inferiority of Focal One robotic HIFU to radical prostatectomy in salvage treatment-free survival (HIFU 89.6% vs. RP 86.2% at 30 months).

1
HIFU also resulted in better outcomes for urinary continence and erectile function.
2
There is no evidence of harmful products or activities. Medicare reimbursement for Focal One HIFU increased by 90% from $4,506 to $8,558 per procedure, effective January 1, 2023, which enhances price accessibility for patients.
3
This increased reimbursement, along with anticipated reimbursement in France, has the potential to increase access for patients, particularly Medicare beneficiaries.
4
As a medical technology company, the KPIs for pharmaceutical patent flexibility, nutrition and food safety, and addiction mitigation are not applicable. The HIFI study, involving over 3,000 patients across 46 centers, suggests strong ethical conduct in clinical trials.
5

Fair Money & Economic Opportunity

0

No evidence available to assess EDAP TMS S.A. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

The provided articles do not contain specific, quantifiable data points for any of the KPIs under the 'Fair Pay & Worker Respect' value. There is no explicit, measurable information regarding living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rates (TRIR), pay equity ratio, worker engagement scores, employee turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.

1
While general statements about 'good labor relations' and compliance with government regulations for employee benefits are present, these are not specific enough to be scored against the rubric's quantitative thresholds.
2

Fair Trade & Ethical Sourcing

0

The provided article, EDAP TMS's Code of Ethics, outlines the company's commitment to ethical conduct, including in supplier relationships.

1
However, it explicitly states that no quantitative data related to fair trade, ethical sourcing, or any of the specific metrics requested for scoring are provided.
2

Honest & Fair Business

0

No specific, concrete evidence was found in the provided articles to assess EDAP.US against any of the 'Honest & Fair Business' KPIs. The articles mention the existence of a code of ethics and a commitment to anti-corruption laws, but lack specific details on policy strength, enforcement, or quantitative metrics for any KPI.

1

Kind to Animals

0

The provided articles do not contain specific, quantifiable data points for any of the 'Kind to Animals' KPIs for EDAP.US.

1
While CrueltyFreeInvesting.org lists EDAP TMS S.A. as having 'No Animal Exploitation', the articles explicitly state 'No data' for all specific metrics such as cruelty-free certification share, alternative testing usage, or animal testing volume.
2
Other articles were not applicable to EDAP.US's practices or the value being assessed. Therefore, all KPIs must be omitted due to lack of specific evidence.

No War, No Weapons

-50

EDAP TMS's core business is medical technology, specifically urology and medical devices, with no evidence of revenue from arms or defense contracts.

1
The company's HIFU technology and ultrasound devices have potential applications in various medical fields, but no evidence suggests development or sale of dual-use technologies with military applications.
2
EDAP TMS complies with sanctions, including those from the U.S. Department of the Treasury’s Office of Foreign Assets Control, and closed its Moscow office due to the conflict in Ukraine, demonstrating adherence to sales restrictions to embargoed regimes.
3
The company adheres to the principles of the Universal Declaration on Human Rights, the International Labor Organization, and the OECD.
4
EDAP-TMS has a Code of Ethics signed by all Directors and Officers, requiring compliance with laws and regulations.
5
It determines business relations in compliance with local laws, internal charters, and requirements in human rights, working conditions, environment, and ethics.
6
The company is continually reviewing its internal control policies and procedures.
7
EDAP-TMS is committed to strict compliance with anticorruption laws and regulations, such as the OECD Convention and the Foreign Corrupt Practices Act.
8
A disclosure Committee has been created to control and discuss information dissemination.
9
The company pays particular attention to ethics, honesty, and compliance with legal and regulatory provisions.
10
EDAP-TMS calls on its suppliers to commit to taking action against corruption.
11

Planet-Friendly Business

0

No specific, concrete data points related to environmental performance, climate targets, resource consumption, waste management, or other Planet-Friendly Business KPIs were found in the provided articles for EDAP.US.

1
The articles primarily focus on financial results, product developments, and regulatory actions, with one article explicitly stating that sustainability data is not available for the company.
2

Respect for Cultures & Communities

0

No evidence available to assess EDAP TMS S.A. on Respect for Cultures & Communities.

Safe & Smart Tech

0

The company states that its data transfers outside the EU are compliant with GDPR and that its cookie management banner is in accordance with new CNIL recommendations.

1
No other specific evidence regarding Safe & Smart Tech KPIs was found in the provided articles.

Zero Waste & Sustainable Products

0

No specific, concrete data points were found across the provided articles to assess EDAP.US against the 'Zero Waste & Sustainable Products' ethical value. Information regarding waste diversion rates, product recyclability percentages, packaging sustainability, recycled content, single-use plastic reduction, take-back program coverage, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education was not explicitly stated with quantitative metrics or specific programs.

1

Own EDAP TMS S.A.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.